Date: 2011-07-04
Type of information: Company acquisition
Acquired company: Bioréalités (France)
Acquiring company: Servier (France)
Amount: undisclosed
Terms: BioRéalités announced its acquisition by Servier. Founded in February 2007, BioRéalités specializes in the development of monoclonal antibodies directed against a key factor in the mechanism of recurrence of cancer, which aims to improve the treatment of several cancers including colorectal cancer. BioRéalités has several drug candidates and a portfolio of patents, the fruit of four years of research within the company and previous work conducted by the research team led by Dominique Joubert and Frederick Holland in the Institute of Functional Genomics Montpellier ( "mixed" unit INSERM, CNRS and University of Montpellier).
Details: In about 80% of colorectal cancers, a genetic mutation causes the abnormal secretion of a particular protein. This molecule is not detected in humans healthy adult. In animal models, Bioréalités showed, using a monoclonal antibody capable of trapping this protein, a reduction in tumor size and better control of recurrences. This therapeutic approach, which acts only on cancer cells, provides a targeted approach to the disease. The main objective is to develop a therapeutic antibody directed against an original target protein, involved in the regulation of such tumor stem cells in colorectal cancer.
Related: Cancer Oncology
